GSK's Avodart reduces prostate cancer risk 23%, raising potential for use beyond BPH
UK drug major GlaxoSmithKline's Avodart (dutasteride) lowered the risk of prostate cancer 23% in a high-risk patient population, according to data presented at the annual meeting of the American Urological Association in Chicago, Illinois.
Headline data from the REDUCE studyshowed that the drug achieved its primary endpoint, demonstrating that dutasteride significantly reduced the risk of all biopsy-detectable prostate cancer by 23% (p<0.0001) over four years. A total of 1,516 cancers were seen, with 659 in the dutasteride arm and 857 in the placebo arm.
The drug inhibits both type 1 and type 2 forms of 5-alpha reductase, which are enzymes responsible for converting testosterone to dihydrotestosterone, the most potent male hormone in the prostate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze